yoteki

Potential Predictive Biomarkers Identified for Perioperative Nivolumab in Lung Cancer

Nature · first seen 12.08.2026

Researchers identify potential predictive biomarkers for perioperative nivolumab therapy benefit in resectable non-small cell lung cancer based on the CheckMate 77T trial.

  • Potential predictive biomarkers for perioperative nivolumab therapy in non-small cell lung cancer have been identified.
  • Findings derive from evaluable participants in the CheckMate 77T clinical trial.

Sources

Also in the feed that day